Foley Hoag to Sponsor American Conference Institute's 6th Annual Summit on Biosimilars
May 17, 2015
Foley Hoag LLP will be the lead sponsor of the American Conference Institute's 6th Annual Summit on Biosimilars, being held at the Affinia Manhattan in New York from June 1- 3, 2015. Foley Hoag partners Donald Ware, Thomas Barker and Barbara Fiacco are speaking.
Ware, who heads Foley Hoag’s Intellectual Property Department, has served as Co-Chair of this three-day event since its inception in 2010. He will provide opening remarks on June 1 with fellow chairs Dr. Seth Fidel, Lead IP Counsel at Merrimack Pharmaceuticals, and Betty Ryberg, VP at Novartis.
Ware will also participate on a panel titled “Declining to Dance? Lessons Learned from Early BPCIA Cases on Whether the Pathway is Mandatory” (June 2). This session will review the biosimilars litigation to date; analyze the substantive issues; and discuss important questions about the BPCIA patent challenge procedures that have yet to be resolved.
Barker, co-chair of Foley Hoag’s Healthcare Practice, will be a panelist on “What’s at Stake: Commercial Opportunity, Risk, and Pricing Considerations for the Emerging U.S. Biosimilars Landscape” (June 2). Barker and his co-panelists will examine the current regulatory landscape for biosimilars, how to navigate the burgeoning U.S. biosimilars market; determine the potential value of U.S. biosimilars revenue; forecast market penetration for biosimilar products; and how to optimize pricing decisions.
Fiacco, another member of Foley Hoag’s Intellectual Property Department, will participate on a panel titled “The Next Battle Ground: Strategies for Obtaining or Challenging Preliminary Injunctions” (June 2). Topics of discussion will include the balance between the streamlined pathway for biosimilars and the procedural protections in place for branded companies; understanding the standard for irreparable harm from illegal market entry; and considerations for first wave versus second wave preliminary injunctions.
The American Conference Institute’s (ACI) Annual Summit on Biosimilars is a forum on the legal, regulatory, patent and commercial realities of follow-on bioglogics. Staffed by industry specialists, lawyers and other professionals, ACI operates as a think tank, monitoring trends and developments in all major industry sectors, the law, and public policy, with a view to providing information on the leading edge.
About Foley Hoag LLP
Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional senior level service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.